Search for: "G T Development " Results 81 - 100 of 3,964
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
1 Sep 2011, 5:01 pm by Oliver G. Randl
Admissibility of the referral[1] In decision G 1/07 [4.2.3] the EBA pointed out that it was aware that, subsequent to decisions G 1/03 and G 2/03 different opinions have been expressed in the jurisprudence of the boards of appeal on whether decisions G 1/03 and G 2/03 relate to the disclaiming of embodiments which are disclosed as part of the invention in the application as filed or whether in that situation the jurisprudence as previously established… [read post]
21 Jun 2010, 5:53 pm by Randall Reese
  The motion asserts that "the Debtors and other key creditors of Gray’s – Société Générale and International Fidelity Insurance Company – do not object to the dismissal of Gray’s’ Chapter 11 case. [read post]
12 May 2010, 3:01 pm by Oliver G. Randl
A 113) or implicitly (e.g. liberty, equality) (see for example G 3/98 [2.5.3]; G 2/02 and G 3/02 [7.2]; T 377/95 [33-36]; T 1193/02 [10]; T 190/03 [10]).The European Patent Organisation is an international, intergovernmental organisation, modelled on a modern state order and based on the separation of powers principle, which the sovereign contracting states have entrusted with the exercise of some of their national powers in the field of… [read post]
28 Nov 2012, 5:01 pm by oliver randl
This it was caused the difficulties both the [applicant] […] and the ED […] faced when trying to reasonably apply condition II of the test, based on the headnote of T 331/87 only.[2.7] But even when condition II is correctly applied, the Board has considerable doubts, at least regarding this aspect of the essentiality test, whether, in view of the narrow interpretation of the [expression] “same invention” according to the more recent case law of the Enlarged Board… [read post]
15 Sep 2020, 1:00 am by Roel van Woudenberg
In the grounds of appeal of 28 March 2019, the applicant referred to T 1063/18 which decided that Rule 28(2) is in conflict with Art.53(b) as interpreted by the Enlarged Board in G 2/12 and G 2/13 and that the refusal in that case based on Rule 28(2) should be set aside. [read post]
6 Mar 2019, 12:24 pm by Roel van Woudenberg
In a communication accompanying the summons to oral proceedings, the Board noted, inter alia, that the case bore some similarity to decision T 1227/05 (OJ EPO 2007, 574), in which the numerical simulation of a noise-affected circuit had been found to be a functional technical feature. [read post]
4 Apr 2022, 7:40 am by Nicole Pottroff
Participants are also allowed to join in mentor/protégé and joint venture relationships to further increase their ability to participate in the American economy. [read post]
8 Feb 2011, 1:09 am by Randall Reese
Updating our previous coverage (see here and here) on Philadelphia Rittenhouse Developer, L.P., the bankrupt developer of 10 Rittenhouse Square, a 33-story condominium building in Philadelphia, the company has now filed its schedules of assets and liabilities and statement of financial affairs with the bankruptcy court. [read post]
11 Jun 2010, 9:00 am by Lucas A. Ferrara, Esq.
Cats that were fed these canned products as their only food are at greater risk for developing signs of thiamine deficiency. [read post]
7 Feb 2012, 5:01 pm by Oliver G. Randl
The criteria developed in G 1/07[6] Before dealing with the criteria of G 1/07 in detail, it is necessary to deal with the proprietor appellants’ assertion that exclusions from patentability should be construed narrowly. [6.1] According to G 1/07 [3.1], a provision containing exclusions or exceptions from patentability is to be interpreted in such a manner that it takes its effect fully and achieves the purpose for which it was designed. [6.2] As further… [read post]
13 Aug 2008, 11:00 am
SPEAKERS: Business development experts Darryl Cross, Michael G. [read post]
26 Aug 2008, 1:49 pm
PRESENTED BY: Professional Business Development Institute (PBDI.org)  SPEAKERS: Larry Bodine, Esq. and Michael G. [read post]
12 Feb 2022, 6:52 pm by Patent Docs
Ravi Srinivasan and Guy Brain of J A Kemp will cover recent developments in the assessment of whether a "plausible" disclosure of efficacy is present in the application as filed, including a discussion of the decision T 116/18 which has for the first time referred the topic of plausibility to the Enlarged Board of Appeal of the European Patent Office (pending as G 2/21). [read post]
12 Sep 2013, 5:01 pm by oliver randl
The starting material for obtaining embryonic stem cells used in the method are blastocysts, i.e. embryos that are about 4 to 7 days old, that already expose some differentiation into an inner cell mass, from which the fetus develops later on, and the trophectoderm, from which extra-embryonic tissues develop […]. [read post]
28 May 2019, 3:45 am by Jessica Kroeze
The disclaimer was consequently allowable under G 1/16 and G 1/03.Auxiliary request III - Novelty vis-à-vis D1The subject-matter of claim 1 was novel over the disclosure in D1. [read post]